Highlights SillaJen, Inc.

Equities

A215600

KR7215600008

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-07 pm EDT			5-day change	1st Jan Change
3,195 ^KRW	+2.40%		-12.23%	-47.01%

Apr. 22	OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	CI
Mar. 27	SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	Apr. 22	CI
SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	Mar. 27	CI
SillaJen to Raise 129.4 Billion Won via Shares Issuance	Mar. 25	MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.	21-11-24	CI
M2N Co.,Ltd signed LOI to acquire SillaJen, Inc..	21-04-20	CI
Sillajen Announces Conclusions from Interim Futility Analysis of Phase 3 PHOCUS Trial in HCC	19-08-02	CI
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)	19-06-06	CI
SillaJen, Inc. Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Cemiplimab	18-06-20	CI
SillaJen, Inc. Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with Sillajen's Pexa-Vec Oncolytic Immunotherapy	18-01-29	CI
SillaJen, Inc. Announces Collaboration with the National Cancer Institute for Development of Combination Therapy	17-08-16	CI
SillaJen and Lee's Pharmaceutical Gets Approval from China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer	17-07-21	CI
Regeneron Pharmaceuticals, Inc. and SillaJen, Inc. Announce New Clinical and Supply Agreement for APhase 1b Dose-Escalation Study in Renal Cell Carcinoma	17-05-08	CI
SillaJen, Inc. has completed an IPO in the amount of KRW 150 billion.	16-12-02	CI
SillaJen, Inc. has filed an IPO.	16-09-12	CI
SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer	16-03-29	CI
SillaJen, Inc. Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer	16-01-05	CI
Transgene and SillaJen Announce Revised Agreement for Oncolytic Viral Therapy	15-11-24	CI
SillaJen Announces Agreement with FDA for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer	15-04-16	CI
SillaJen, Inc. completed the acquisition of the remaining stake in Jennerex Biotherapeutics, Inc. from Transgene SA and others.	14-03-17	CI
SillaJen, Inc. executed a definitive merger agreement to acquire remaining stake in Jennerex Biotherapeutics, Inc. for approximately $150 million.	13-11-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SillaJen, Inc.

Equities

A215600

KR7215600008

Highlights

Filters